Homepage
Author:
Aura Biosciences, Inc.
Posted Date:
May 12, 2026
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, Inc.
May 12, 2026
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences, Inc.
May 11, 2026
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aura Biosciences, Inc.
May 5, 2026
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Aura Biosciences, Inc.
May 4, 2026
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences, Inc.
May 4, 2026
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Aura Biosciences, Inc.
May 4, 2026
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Aura Biosciences, Inc.
March 30, 2026
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, Inc.
February 25, 2026
